-
Raising the standards of care
With our proprietary focused heat technology platforms, our treatments are minimally invasive, non-toxic. We are leading the way in new developments in cancerous and non-cancerous treatments for breast disease and BPH.
Read More -
Improve the Outcome
Our goal is to improve outcomes and standards of care in cancerous and non-cancerous treatments. Clinical studies have demonstrated that when used in conjunction with chemotherapy for breast cancer, Medifocus’ patented APA system can significantly increase tumor shrinkage by...
Read More -
Medical Professionals
Medifocus develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with comprehensive...
Read More -
Minimally Invasive
Our focused heat treatment systems are designed with patients’ needs and comfort in mind. They are minimally invasive, nontoxic, and have little to no side effects.
Read More -
Better Cancer Treatment Options
The future goal for Medifocus is to further expand the capabilities of its APA microwave focusing technology platform to develop and commercialize other focused heat treatment systems for surface, subsurface and deep seated tumors anywhere in the body.
Read More
"Improving the outcomes and standards of care in cancerous and benign conditions with minimally invasive focused heat technologies."
Our treatment is designed with patients' needs and comfort in mind.
Who We Are
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with approximately 100 issued and pending US and international patents:
ReadMoreThe Prolieve® System
Our Prolieve Thermodilatation System was originally developed and commercialized by the current Medifocus management, product development, clinical and regulatory teams. In June 2012, Medifocus reached an agreement with Boston Scientific for the purchase of all of the assets of its Prolieve business,including all Prolieve inventory, the Rocky Mountain Mobile
ReadMore